Roche Pharmaceuticals

MIRCERA Abstracts Ranked Among the Best at Upcoming European Nephrology Congress

Basel, Switzerland (ots/PRNewswire) - Eight presentations regarding Roche's new anti-anaemia drug MIRCERA(R) currently awaiting approval worldwide, will feature strongly at the upcoming European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress in Barcelona Spain, June 21st to 24th 2007. Three MIRCERA abstracts have received the accolade of being among the top eight best abstracts (out of 1191) accepted by the congress this year. In addition, Roche's current anaemia treatment NeoRecormon(R) has 3 poster presentations of data from its ongoing GAIN, IRIDIEM and ORAMA studies. Details of the MIRCERA and NeoRecormon results will be available concurrent with when they are presented at the congress. Please note all information presented at the annual meeting is embargoed for media release until one hour after the time of presentation. Summary of presentations Author Abstract Title Presentation Date & Time Type of Presentation MIRCERA Presentations Mann et al. C.E.R.A. provides stable Oral 09:00 - haemoglobin (Hb) levels in CKD 10:30 (Awarded best patients on dialysis with and abstract) without coronary artery disease Sunday, June (CAD) or diabetes mellitus (DM) 24 when administered once monthly Ryckelynck et Once-monthly C.E.R.A. maintains Oral 09:00 - al. stable haemoglobin 10:30 concentrations in dialysis (Awarded best patients regardless of gender Sunday, June abstract) or age 24 Walker et al. C.E.R.A. corrects anaemia and Oral 09:00 - maintains stable haemoglobin 10:30 (Awarded best (Hb) levels at extended abstract) administration intervals in a Sunday, June 52-week study of patients with 24 chronic kidney disease (CKD) not on dialysis Imbasciati et Stable haemoglobin (Hb) levels Oral 09:00 - al. are maintained with 10:30 once-monthly C.E.R.A. in dialysis patients with varying Sunday, June C-reactive protein (CRP), 24 albumin or dialysis adequacy Chanu et al. Pharmacokinetic parameters of Poster C.E.R.A. are not affected by age in patients with chronic 10.30 to kidney disease on dialysis 12.00 hrs Saturday, June 23 Chanu et al. Pharmacokinetics of C.E.R.A. Poster 10.30 to and stable maintenance of 12.00 hrs haemoglobin (Hb) levels with once-monthly dosing in Saturday, patients with chronic kidney June 23 disease (CKD) Locatelli et al. The effect of iron status on Poster 10.30 to haemoglobin (Hb) stability in 12.00 hrs patients with chronic kidney disease (CKD) treated with Saturday, once-monthly C.E.R.A. June 23 Saueressig et Staff time and costs for Poster 10.30 to al. anaemia management with 12.00 hrs erythropoietic stimulating agents in patients on Saturday, haemodialysis June 23 NeoRecormon Presentations Wanner et al. The IRIDIEM survey: CVD Poster 10.30 to parameters in patients with 12.00 hrs chronic kidney disease and type 2 diabetes are consistently Friday, June under target 22 Locatelli et al. Do guideline-based computer Poster 10.30 to prompts improve clinical 12.00 hrs practice in dialysis patients? - preliminary results of ORAMA Saturday, study June 23 Rath et al. Hb management in GAIN: dose Poster 10.30 to saving and administration 12.00 hrs frequency - final results Saturday, June 23 Interested journalists may view the meeting schedule online at http://www.eraedta2007.org. ots Originaltext: Roche Pharmaceuticals Im Internet recherchierbar: http://www.presseportal.ch Contact: For more information, please contact: Sheila Gies at Roche, Tel: +973-235-4347, Mobile: +973-687-0188, Diane Lorton at Galliard Healthcare, Tel: +44-(0)207663-2265, Mobile: +44-(0)7811-358-698

Das könnte Sie auch interessieren: